Active — Not RecruitingPhase 2

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

United States25 participantsStarted 2022-03-01

Plain-language summary

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a study drug called fedratinib in participants with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 negative
✓. Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U)
✓. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
✓. Chronic Neutrophilic Leukemia (CNL).

What they're measuring

Objective Clinical Response Rate

Timeframe: Up to 24 weeks

Trial details

NCT IDNCT05177211

SponsorH. Lee Moffitt Cancer Center and Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-10

Results submitted2026-03-26

View on ClinicalTrials.gov More Myeloproliferative Neoplasm trials